Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 30;16(9):e70567.
doi: 10.7759/cureus.70567. eCollection 2024 Sep.

Length of Stay, Readmission Rates, and Mortality Are Similar Between Hospitalized Individuals With Sickle Cell Disease With and Without COVID-19

Karen A Clarke  1 , Mohamad Moussa  1 , Mary Ann Kirkconnell Hall  1 , Yoo Mee Shin  1
Affiliations

Length of Stay, Readmission Rates, and Mortality Are Similar Between Hospitalized Individuals With Sickle Cell Disease With and Without COVID-19

Karen A Clarke et al. Cureus. .

Abstract

Background We sought to clarify the impact of COVID-19 on clinical outcomes in sickle cell disease patients, given their baseline hypercoagulable state in combination with COVID-19-related coagulopathies and other complications. Methods Retrospective chart review of two groups of sickle cell disease patients hospitalized between March 2020 to December 2021: Group 1 did not have COVID-19 (n = 95) and Group 2 did (n = 73). Results Groups 1 and 2 were similar in terms of age, race, sex, comorbid illnesses, genotype, hydroxyurea use, and opioid use. Group 1 and 2 patients had a mean hospital length of stay of 7.05 and 7.64 days, respectively (p = 0.981). ICU-level care was required for six (6.3%) Group 1 patients and four (5.5%) Group 2 patients (p = 1.000). Readmissions within 30 days occurred for 25 (26.3%) Group 1 patients, and 18 (24.7%) Group 2 patients (p = 0.807). Death occurred for one (1.05%) Group 1 patient and one (1.4%) Group 2 patient (p = 1.000). There were no significant differences in commonly ordered initial laboratory values (total bilirubin, hemoglobin, hematocrit, creatinine, lactate dehydrogenase, and D-dimer) between Group 1 and Group 2 patients. Conclusions We observed no significant differences in clinical outcomes among sickle cell disease patients hospitalized due to COVID-19 compared to those without COVID-19.

Keywords: clinical outcomes; covid-19; length of stay; mortality; sickle cell disease.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Numbers of patients admitted with COVID-19 during each month of study period
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. WHO coronavirus (COVID-19) dashboard. [ Jun; 2024 ]. 2024. https://covid19.who.int https://covid19.who.int
    1. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. Dessie ZG, Zewotir T. BMC Infect Dis. 2021;21:855. - PMC - PubMed
    1. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Piel FB, Patil AP, Howes RE, et al. Lancet. 2013;381:142–151. - PMC - PubMed
    1. Sickle cell disease. Piel FB, Steinberg MH, Rees DC. N Engl J Med. 2017;376:1561–1573. - PubMed
    1. Sickle cell disease: a primary care update. Onimoe G, Rotz S. Cleve Clin J Med. 2020;87:19–27. - PubMed

LinkOut - more resources